Evaluation studies confirm improved oncology patient pathways through HORIBA Medical’s new POC haematology analyser

13 July 2018


Yumizen H500 full blood count analyser demonstrates exceptional correlation with larger laboratory-based systems

HORIBA Medical’s Yumizen H500 compact haematology analyser

HORIBA Medical’s Yumizen H500 compact haematology analyser enhancing POCT and care of oncology patients

HORIBA UK Ltd, Medical announces the publication of two studies successfully evaluating the use of its Yumizen H500 haematology analyser for point-of-care testing (POCT) to enhance the care of oncology patients. With near-patient, full blood count results, patients undergoing chemotherapy can receive treatment without delay and greatly reduce their hospital/clinic exposure times. Both UK-based studies were presented at the recent ISLH 2018 (International Symposium on Technical Innovations in Laboratory Haematology) in Brussels.

The evaluation studies were performed by the Cardiff and Vale Health Board (CAVHB), University Hospital of Wales [1] and the Spire Bushey Laboratory, London [2] and can be viewed on the HORIBA Medical global website. Both studies demonstrated that the compact, easy-to-use analyser delivered at the POC clinically key parameters that showed exceptional correlation with larger laboratory-based haematology analysers. Blood samples from oncology patients may be abnormal, having low counts and atypical blood cells, therefore it is essential that near-patient testing does not compromise the clinical integrity of results.

The studies both found that in addition to speed and ease of use, the Yumizen H500’s functionality and audit systems fully adhere to ISO standards (both 15189:2012 and 22870:2016) with the same internal quality controls as larger analysers. This is turn ensured detailed, accurate results for timely and sound clinical decision making.

For example, the Cardiff study concluded that by using the Yumizen H500, “In CAVHB the potential for clinical improvement is potentially vast, average TAT (vein to report) for FBC is ~4 hours, this could be reduced to <15 minutes. This would mean that in certain patient groups (thrombocytopenic and anaemic) they can request blood components earlier and be transfused more quickly, this in turn would reduce hospital stays. In neutropenic patients their treatment options could be considered more readily and reduce hospital/clinic exposure time in those that would not be appropriate for chemotherapy.”

HORIBA Medical’s Yumizen H500 compact haematology analyser ensures safe and easy diagnosis by delivering timely and reliable results. With just three reagents and an intuitive touch screen user interface, it is designed for ease of use; yet it offers a range of clinically key parameters, including: 5-population WBC differential, red blood cell parameters and platelet count. This makes the Yumizen H500 the most flexible solution to rapid blood counting for use in POC settings for paediatric care and chemotherapy patients, as well as from emergency care to the routine laboratory.

The two POCT studies presented at ISLH 2018 can be viewed at: https://www.horiba.com/en_en/products/by-segment/medical/.

For more information on HORIBA UK Ltd. Medical and its products, please visit: www.horiba.com/uk/medical. Specific information on the Yumizen H500 FBC analyser can be found at: http://www.horiba.com/uk/medical/products/hematology/yumizen-h500/

References:
1)    Boyland, D. and Ingram, L. (2018). Evaluation of the Yumizen H500 FBC analyser and potential clinical improvements for point of care testing for paediatric patient groups. Presented at ISLH Symposium – May 2018
2)    Amin, K. and Gabiows, K. (2018). An evaluation of the Yumizen H500 FBC analyser for near-patient testing with oncology patients. Presented at ISLH Symposium – May 2018.